Jacobus Pharmaceutical Company, Inc., Petitioner v. Catalyst Pharmaceuticals, Inc., et al.
-
July 12, 2022
Catalyst Inks Deal To End Its 'Orphan Drug' Case
Florida-based Catalyst Pharmaceuticals Inc. has inked a deal to settle its patent case against a rival involving a drug that treats a rare autoimmune disease, ending litigation that made its way to the U.S. Supreme Court.
-
April 12, 2022
11th Circ. Undermined Rare-Disease Drugs, High Court Told
Jacobus Pharmaceutical Co. Inc. said that the Eleventh Circuit created a circuit split and upended years of U.S. Food and Drug Administration policy when it ruled lucrative exclusivity for so-called orphan drugs extends not just to the specific approved uses but rather the entire drug.